Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 45
Filtrar
1.
Xenobiotica ; 52(8): 828-839, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-36039395

RESUMO

Many peptide drugs such as insulin and glucagon-like peptide (GLP-1) analogues are successfully administered subcutaneously (SC). Following SC injection, peptides may undergo catabolism in the SC compartment before entering systemic circulation, which could compromise their bioavailability and in turn affect their efficacy.This review will discuss how both technology and strategy have evolved over the past years to further elucidate peptide SC catabolism.Modern bioanalytical technologies (particularly liquid chromatography-high-resolution mass spectrometry) and bioinformatics platforms for data mining has prompted the development of in silico, in vitro and in vivo tools for characterising peptide SC catabolism to rapidly address proteolytic liabilities and, ultimately, guide the design of peptides with improved SC bioavailability.More predictive models able to recapitulate the interplay between SC catabolism and other factors driving SC absorption are highly desirable to improve in vitro/in vivo correlations.We envision the routine incorporation of in vitro and in vivo SC catabolism studies in ADME screening funnels to develop more effective peptide drugs for SC delivery.


Assuntos
Insulina , Peptídeos , Peptídeos/metabolismo , Preparações Farmacêuticas , Disponibilidade Biológica , Cromatografia Líquida , Injeções Subcutâneas
2.
ACS Med Chem Lett ; 14(5): 645-651, 2023 May 11.
Artigo em Inglês | MEDLINE | ID: mdl-37197453

RESUMO

Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is the first reported nonreceptor oncogenic tyrosine phosphatase connecting multiple signal transduction cascades and exerting immunoinhibitory function through the PD-1 checkpoint receptor. As part of a drug discovery program aimed at obtaining novel allosteric SHP2 inhibitors, a series of pyrazopyrazine derivatives bearing an original bicyclo[3.1.0]hexane basic moiety on the left-hand side region of the molecule were identified. We report herein the discovery process, the in vitro pharmacological profile, and the early developability features of compound 25, one of the most potent members of the series.

3.
ACS Med Chem Lett ; 14(2): 156-162, 2023 Feb 09.
Artigo em Inglês | MEDLINE | ID: mdl-36793438

RESUMO

Protein tyrosine phosphatase SHP2 is an oncogenic protein that can regulate different cytokine receptor and receptor tyrosine kinase signaling pathways. We report here the identification of a novel series of SHP2 allosteric inhibitors having an imidazopyrazine 6,5-fused heterocyclic system as the central scaffold that displays good potency in enzymatic and cellular assays. SAR studies led to the identification of compound 8, a highly potent SHP2 allosteric inhibitor. X-ray studies showed novel stabilizing interactions with respect to known SHP2 inhibitors. Subsequent optimization allowed us to identify analogue 10, which possesses excellent potency and a promising PK profile in rodents.

4.
Antimicrob Agents Chemother ; 56(8): 4161-7, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22615282

RESUMO

HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections. Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon. In this communication, we report the preclinical profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clinical development. The compound demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors. In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies. In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing. When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body weight twice daily (b.i.d.) for 7 days. Based on its preclinical profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clinically important resistance variants and highly suited for incorporation into newer all-oral regimens.


Assuntos
Hepacivirus/efeitos dos fármacos , Inibidores de Proteases/farmacologia , Quinoxalinas/farmacologia , Quinoxalinas/farmacocinética , Proteínas não Estruturais Virais/antagonistas & inibidores , Amidas , Animais , Antivirais/farmacologia , Carbamatos , Ciclopropanos , Cães , Farmacorresistência Viral , Genótipo , Hepacivirus/enzimologia , Hepacivirus/genética , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/virologia , Fígado/efeitos dos fármacos , Pan troglodytes , Quinoxalinas/metabolismo , Ratos , Sulfonamidas , Carga Viral/efeitos dos fármacos
5.
Bioorg Med Chem ; 20(15): 4801-11, 2012 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-22770556

RESUMO

Previous investigations in our laboratories resulted in the discovery of a novel series of potent nucleoside inhibitors of Hepatitis C virus (HCV) NS5B polymerase bearing tetracyclic 7-substituted 7-deaza-adenine nucleobases. The planarity of such modified systems was suggested to play a role in the high inhibitory potency observed. This paper describes how we envisaged to maintain the desired planarity of the modified nucleobase by means of an intra-molecular H-bond, engaging a H-bond donor atom on an appropriately substituted 7-heterocyclic residue with the adjacent amino group of the nucleobase. The success of this strategy is reflected by the identification of several novel potent nucleoside inhibitors of HCV NS5B bearing a 7-heterocyclic substituted 7-deaza-adenine nucleobase. Amongst these, the 1,2,4-oxadiazole analog 11 showed high antiviral potency against HCV replication in replicon cells and efficient conversion to the corresponding NTP in vivo, with high and sustained levels of NTP measured in rat liver following intravenous and oral administration.


Assuntos
Antivirais/farmacologia , Inibidores Enzimáticos/farmacologia , Hepacivirus/efeitos dos fármacos , Nucleosídeos/farmacologia , Proteínas não Estruturais Virais/antagonistas & inibidores , Antivirais/síntese química , Antivirais/química , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/química , Testes de Sensibilidade Microbiana , Estrutura Molecular , Nucleosídeos/síntese química , Nucleosídeos/química , Replicon/efeitos dos fármacos , Relação Estrutura-Atividade , Proteínas não Estruturais Virais/metabolismo , Replicação Viral/efeitos dos fármacos
6.
Mol Cancer Ther ; 21(2): 282-293, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34815361

RESUMO

The innate immune agonist STING (STimulator of INterferon Genes) binds its natural ligand 2'3'-cGAMP (cyclic guanosine-adenosine monophosphate) and initiates type I IFN production. This promotes systemic antigen-specific CD8+ T-cell priming that eventually provides potent antitumor activity. To exploit this mechanism, we synthesized a novel STING agonist, MSA-1, that activates both mouse and human STING with higher in vitro potency than cGAMP. Following intratumoral administration of MSA-1 to a panel of syngeneic mouse tumors on immune-competent mice, cytokine upregulation and its exposure were detected in plasma, other tissues, injected tumors, and noninjected tumors. This was accompanied by effective antitumor activity. Mechanistic studies in immune-deficient mice suggested that antitumor activity of intratumorally dosed STING agonists is in part due to necrosis and/or innate immune responses such as TNF-α activity, but development of a robust adaptive antitumor immunity is necessary for complete tumor elimination. Combination with PD-1 blockade in anti-PD-1-resistant murine models showed that MSA-1 may synergize with checkpoint inhibitors but can also provide superior tumor control as a single agent. We show for the first time that potent cyclic dinucleotides can promote a rapid and stronger induction of the same genes eventually regulated by PD-1 blockade. This may have contributed to the relatively early tumor control observed with MSA-1. Taken together, these data strongly support the development of STING agonists as therapy for patients with aggressive tumors that are partially responsive or nonresponsive to single-agent anti-PD-1 treatment by enhancing the anti-PD-1 immune profile.


Assuntos
Imunidade Inata/imunologia , Imunoterapia/métodos , Interferons/metabolismo , Neoplasias/imunologia , Animais , Linhagem Celular Tumoral , Feminino , Humanos , Camundongos
7.
Bioorg Med Chem Lett ; 21(15): 4429-35, 2011 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-21737263

RESUMO

The Hedgehog (Hh-) signaling pathway is a key developmental pathway which gets reactivated in many human tumors, and smoothened (Smo) antagonists are emerging as novel agents for the treatment of malignancies dependent on the Hh-pathway, with the most advanced compounds demonstrating encouraging results in initial clinical trials. A novel series of potent bicyclic hydantoin Smo antagonists was reported in the preceding article, these have been resolved, and optimized to identify potent homochiral derivatives with clean off-target profiles and good pharmacokinetic properties in preclinical species. While showing in vivo efficacy in mouse allograft models, unsubstituted bicyclic tetrahydroimidazo[1,5-a]pyrazine-1,3(2H,5H)-diones were shown to epimerize in plasma. Alkylation of the C-8 position blocks this epimerization, resulting in the identification of MK-5710 (47) which was selected for further development.


Assuntos
Antineoplásicos/química , Proteínas Hedgehog/antagonistas & inibidores , Imidazóis/química , Pirazinas/química , Animais , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapêutico , Cães , Proteínas Hedgehog/metabolismo , Humanos , Imidazóis/farmacologia , Imidazóis/uso terapêutico , Camundongos , Neoplasias/tratamento farmacológico , Pirazinas/farmacologia , Pirazinas/uso terapêutico , Ratos , Transdução de Sinais/efeitos dos fármacos , Estereoisomerismo , Relação Estrutura-Atividade
8.
Oncoimmunology ; 10(1): 1896643, 2021 03 18.
Artigo em Inglês | MEDLINE | ID: mdl-33796403

RESUMO

Prostaglandin E2 (PGE2), an arachidonic acid pathway metabolite produced by cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through engagement with one or more E-type prostanoid receptors (EP1-4). Specific targeting of EP receptors, as opposed to COX-1/2 inhibition, has been proposed to achieve preferential antagonism of PGE2-mediated immune suppression. Here we describe the anti-tumor activity of MF-766, a potent and highly selective small-molecule inhibitor of the EP4 receptor. EP4 inhibition by MF-766 synergistically improved the efficacy of anti-programmed cell death protein 1 (PD-1) therapy in CT26 and EMT6 syngeneic tumor mouse models. Multiparameter flow cytometry analysis revealed that treatment with MF-766 promoted the infiltration of CD8+ T cells, natural killer (NK) cells and conventional dendritic cells (cDCs), induced M1-like macrophage reprogramming, and reduced granulocytic myeloid-derived suppressor cells (MDSC) in the tumor microenvironment (TME). In vitro experiments demonstrated that MF-766 restored PGE2-mediated inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production in THP-1 cells and human blood, and PGE2-mediated inhibition of interleukin (IL)-2-induced interferon (IFN)-γ production in human NK cells. MF-766 reversed the inhibition of IFN-γ in CD8+ T-cells by PGE2 and impaired suppression of CD8+ T-cells induced by myeloid-derived suppressor cells (MDSC)/PGE2. In translational studies using primary human tumors, MF-766 enhanced anti-CD3-stimulated IFN-γ, IL-2, and TNF-α production in primary histoculture and synergized with pembrolizumab in a PGE2 high TME. Our studies demonstrate that the combination of EP4 blockade with anti-PD-1 therapy enhances antitumor activity by differentially modulating myeloid cell, NK cell, cDC and T-cell infiltration profiles.


Assuntos
Linfócitos T CD8-Positivos , Receptores de Prostaglandina E Subtipo EP4 , Animais , Ciclo-Oxigenase 2 , Dinoprostona , Macrófagos , Camundongos
9.
Bioanalysis ; 12(24): 1757-1766, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33259228

RESUMO

Drug discovery is moving at a rapid pace and a fast turnaround of bioanalytical data is needed to sustain this pace. This article focuses on the evaluation of time-saving homogeneous proximity immunoassays such as Amplified Luminescent Proximity Homogeneous Assay, Time-Resolved Fluorescence Resonance Energy Transfer and Spatial Proximity Analyte Reagent Capture Luminescence as an alternative to industry popular platforms like mesoscale discovery (MSD) and Gyrolab®. Our evaluation showed that no one platform can be considered the best for all the parameters assessed. Homogeneous proximity platforms were found to be advantageous over MSD and Gyrolab for certain applications and are herein discussed. The factors affecting the performance of homogeneous assays and appropriate corrections are discussed. The homogeneous assays, due to their flexibility, hold a lot of untapped potential for the future of bioanalysis.


Assuntos
Descoberta de Drogas/métodos , Imunoensaio/métodos , Humanos
10.
Bioorg Med Chem Lett ; 19(5): 1392-5, 2009 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-19181520
11.
J Sep Sci ; 32(9): 1275-83, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19347863

RESUMO

A very accurate and selective LC-MS/MS method was developed and validated for the quantification of 2'-C-modified nucleoside triphosphate in liver tissue samples. An efficient pretreatment procedure of liver tissue samples was developed, using a fully automated SPE procedure with 96-well SPE plate (weak anion exchange sorbent, 30 mg). Nucleotide hydrophilic interaction chromatography has been performed on an aminopropyl column (100 mm x 2.0 mm, 3 microm) using a gradient mixture of ACN and ACN/water (5:95 v/v) with 20 mM ammonium acetate at pH 9.45 as mobile phase at 300 microL/min flow rate. The 2'-C-modified nucleoside triphosphate was detected in the negative ESI mode in multiple reaction monitoring (MRM) mode. Calibration curve was linear over the 0.05-50 microM concentration range. Satisfying results, confirming the high reliability of the established LC-MS/MS method, were obtained for intraday precision (CV = 2.5-9.1%) and accuracy (92.6-94.8%) and interday precision (CV = 9.6-11.5%) and accuracy (94.4-102.4%) as well as for recovery (82.0-112.6%) and selectivity. The method has been successfully applied for pharmacokinetic studies of 2'-C-methyl-cytidine-triphosphate in liver tissue samples.


Assuntos
Citidina Trifosfato/análogos & derivados , Citidina Trifosfato/análise , Fígado/química , Espectrometria de Massas em Tandem/métodos , Animais , Antivirais/administração & dosagem , Antivirais/metabolismo , Calibragem , Cromatografia Líquida/métodos , Masculino , Pró-Fármacos/administração & dosagem , Pró-Fármacos/metabolismo , Nucleosídeos de Pirimidina/administração & dosagem , Nucleosídeos de Pirimidina/metabolismo , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Extração em Fase Sólida/métodos , Solventes/química
12.
ACS Med Chem Lett ; 9(12): 1193-1198, 2018 Dec 13.
Artigo em Inglês | MEDLINE | ID: mdl-30613325

RESUMO

We report herein the design and synthesis of a series of orally active, liver-targeted hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors for the treatment of anemia. In order to mitigate the concerns for potential systemic side effects, we pursued liver-targeted HIF-PHD inhibitors relying on uptake via organic anion transporting polypeptides (OATPs). Starting from a systemic HIF-PHD inhibitor (1), medicinal chemistry efforts directed toward reducing permeability and, at the same time, maintaining oral absorption led to the synthesis of an array of structurally diverse hydroxypyridone analogues. Compound 28a was chosen for further profiling, because of its excellent in vitro profile and liver selectivity. This compound significantly increased hemoglobin levels in rats, following chronic QD oral administration, and displayed selectivity over systemic effects.

13.
J Cataract Refract Surg ; 33(2): 203-9, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17276259

RESUMO

PURPOSE: To study optical aberrations in eyes having uneventful cataract surgery and in-the-bag implantation of an aspherical Tecnis Z9000 intraocular lens (IOL) (AMO) or a spherical CeeOn Edge 911 IOL (Pharmacia) and compare the results with those in a group of phakic age-matched eyes. SETTING: Ophthalmic Unit, Hospital and University of Verona, Verona, Italy. MATERIALS: Three groups, each with 30 patients (30 eyes), were examined with the Topcon KR-9000PW topographer/aberrometer. Spherical aberration and coma were analyzed in detail for 4.0 mm optical zone. Internal values were obtained by subtracting corneal aberrations from ocular aberrations. Point spread function and modulation transfer function (MTF) were considered for optical quality. RESULTS: The mean internal spherical aberration Z(4)(0) was -0.048 microm +/- 0.017 (SD) in the Tecnis group, +0.033 +/- 0.026 microm in the 911 Edge group (P<.001), and -0.013 +/- 0.056 microm in the phakic group (P = .149). The mean internal vertical coma Z(3)(-1) was 0.087 +/- 0.056 microm, 0.054 +/- 0.043 microm (P = .005), and 0.044 +/- 0.044 microm (P<.001), respectively. The internal horizontal coma Z(3)(+1) showed a similar pattern; however, total resulting coma was similar in the 3 groups. The mean Strehl ratio was 0.284 +/- 0.166 in the Tecnis group, 0.145 +/- 0.077 in the 911 Edge group (P<.01), and 0.164 +/- 0.097 in the phakic group (P<.01). The MTF curve was better in the Tecnis group (P<.001). CONCLUSIONS: After uneventful implantation, the aspherical IOL yielded better ocular aberration and optical quality results than the spherical IOL. Induced coma was somewhat higher in the Tecnis group; however, the overall results were not affected. Physiologic IOL decentration after correct in-the-bag implantation did not negate the advantages of asphericity.


Assuntos
Lentes Intraoculares , Facoemulsificação , Pseudofacia/fisiopatologia , Erros de Refração/fisiopatologia , Idoso , Idoso de 80 Anos ou mais , Topografia da Córnea , Feminino , Humanos , Implante de Lente Intraocular , Masculino , Pessoa de Meia-Idade , Desenho de Prótese , Refração Ocular/fisiologia , Estudos Retrospectivos , Acuidade Visual/fisiologia
14.
J Ocul Pharmacol Ther ; 33(2): 123-127, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28048946

RESUMO

PURPOSE: To describe the outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in the treatment of retinal angiomatous proliferation (RAP) in real-life practice in 7 Italian centers under the Progetto Luce initiative. METHODS: Clinical data of 95 eyes of 95 patients affected by RAP, regularly followed up and treated with either intravitreal ranibizumab or bevacizumab over 12 months, were examined. After a loading phase of 3 consecutive injections, retreatments were administered following a pro-re-nata regimen on the basis of the persistence or the recurrence of subretinal/intraretinal fluid on optical coherence tomography, or leakage on fluorescein angiography. RESULTS: Overall, the mean best corrected visual acuity changed from 0.66 to 0.53 LogMAR (P: 0.0003); 36.8% of eyes gained at least 3 ETDRS lines, whereas 13.7% lost >3 lines at the end of the follow-up. Mean central retinal thickness improved from 384 µm at baseline to 262 µm at the 12-month examination (P < 0.001). A serous pigment epithelium detachment (PED) was identified in 68.4% of eyes at baseline, and it was still detectable in 30.5% at the end of follow-up. The mean number of injections was 4.4 over the follow-up. A significantly greater proportion of eyes showed PED resolution in the subgroup treated with ranibizumab (P < 0.001). CONCLUSIONS: Intravitreal anti-VEGF treatment in routine clinical practice allows a significant improvement in visual function in patients affected by RAP. A limited number of anti-VEGF injections are generally required in most cases.


Assuntos
Inibidores da Angiogênese/uso terapêutico , Bevacizumab/uso terapêutico , Neovascularização de Coroide/tratamento farmacológico , Ranibizumab/uso terapêutico , Neovascularização Retiniana/tratamento farmacológico , Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Inibidores da Angiogênese/administração & dosagem , Bevacizumab/administração & dosagem , Feminino , Angiofluoresceinografia , Humanos , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Ranibizumab/administração & dosagem , Estudos Retrospectivos , Tomografia de Coerência Óptica , Fatores de Crescimento do Endotélio Vascular/metabolismo
15.
Sci Rep ; 7(1): 13853, 2017 10 23.
Artigo em Inglês | MEDLINE | ID: mdl-29062039

RESUMO

Mutations in IDH1 are highly prevalent in human glioma. First line treatment is radiotherapy, which many patients often forego to avoid treatment-associated morbidities. The high prevalence of IDH1 mutations in glioma highlights the need for brain-penetrant IDH1 mutant-selective inhibitors as an alternative therapeutic option. Here, we have explored the utility of such an inhibitor in IDH1 mutant patient-derived models to assess the potential therapeutic benefits associated with intracranial 2-HG inhibition. Treatment of mutant IDH1 cell line models led to a decrease in intracellular 2-HG levels both in vitro and in vivo. Interestingly, inhibition of 2-HG production had no effect on in vitro IDH1 mutant glioma cell proliferation. In contrast, IDH1 mutant-selective inhibitors provided considerable survival benefit in vivo. However, even with near complete inhibition of intratumoral 2-HG production, not all mutant glioma models responded to treatment. The results suggest that disruption of 2-HG production with brain-penetrant inhibitors in IDH1 mutant gliomas may have substantial patient benefit.


Assuntos
Neoplasias Encefálicas/mortalidade , Inibidores Enzimáticos/farmacologia , Glioma/mortalidade , Glutaratos/metabolismo , Isocitrato Desidrogenase/antagonistas & inibidores , Proteínas Mutantes/antagonistas & inibidores , Mutação , Adulto , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/genética , Feminino , Perfilação da Expressão Gênica , Glioma/tratamento farmacológico , Glioma/genética , Humanos , Isocitrato Desidrogenase/genética , Isocitrato Desidrogenase/metabolismo , Camundongos Endogâmicos C57BL , Camundongos SCID , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Taxa de Sobrevida , Ensaios Antitumorais Modelo de Xenoenxerto
16.
Clin Cancer Res ; 21(8): 1916-24, 2015 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-25609063

RESUMO

PURPOSE: Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide. EXPERIMENTAL DESIGN: In vitro MK-1775 efficacy alone and in combination with temozolomide, and the impact on DNA damage, was analyzed by Western blotting and γH2AX foci formation. In vivo efficacy was evaluated in orthotopic and heterotopic xenografts. Drug distribution was assessed by conventional mass spectrometry (MS) and matrix-assisted laser desorption/ionization (MALDI)-MS imaging. RESULTS: GBM22 (IC50 = 68 nmol/L) was significantly more sensitive to MK-1775 compared with five other GBM xenograft lines, including GBM6 (IC50 >300 nmol/L), and this was associated with a significant difference in pan-nuclear γH2AX staining between treated GBM22 (81% cells positive) and GBM6 (20% cells positive) cells. However, there was no sensitizing effect of MK-1775 when combined with temozolomide in vitro. In an orthotopic GBM22 model, MK-1775 was ineffective when combined with temozolomide, whereas in a flank model of GBM22, MK-1775 exhibited both single-agent and combinatorial activity with temozolomide. Consistent with limited drug delivery into orthotopic tumors, the normal brain to whole blood ratio following a single MK-1775 dose was 5%, and MALDI-MS imaging demonstrated heterogeneous and markedly lower MK-1775 distribution in orthotopic as compared with heterotopic GBM22 tumors. CONCLUSIONS: Limited distribution to brain tumors may limit the efficacy of MK-1775 in GBM.


Assuntos
Barreira Hematoencefálica/metabolismo , Dacarbazina/análogos & derivados , Glioblastoma/metabolismo , Glioblastoma/patologia , Pirazóis/farmacologia , Pirimidinas/farmacologia , Animais , Proteínas de Ciclo Celular/antagonistas & inibidores , Dano ao DNA/efeitos dos fármacos , Dacarbazina/farmacocinética , Dacarbazina/farmacologia , Modelos Animais de Doenças , Glioblastoma/tratamento farmacológico , Glioblastoma/mortalidade , Humanos , Camundongos , Proteínas Nucleares/antagonistas & inibidores , Proteínas Tirosina Quinases/antagonistas & inibidores , Pirazóis/farmacocinética , Pirimidinas/farmacocinética , Pirimidinonas , Temozolomida , Carga Tumoral/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto
17.
Curr Med Chem ; 11(3): 279-96, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-14965232

RESUMO

The development of new "atypical" antipsychotic agents, which are safer than classical neuroleptics and also active against the negative symptoms and neurocognitive deficits caused by the illness, has produced a significant advancement in the treatment of schizophrenia. The atypical (or "second generation") antipsychotics have several therapeutical properties in common, however they can significantly differ with regard to clinical potency and side effects. The main features regarding pharmacodynamics, pharmacokinetics and pharmacological interactions of the most important atypical antipsychotics, namely clozapine, olanzapine, quetiapine and risperidone, are treated herein. Several analytical methods available for the therapeutic drug monitoring of these drugs are also presented, as well as the novel formulations, which can notably improve the therapy of schizophrenia. Other very recent atypical agents, such as ziprasidone, aripiprazole, iloperidone, sertindole and zotepine will also be briefly described.


Assuntos
Antipsicóticos/farmacocinética , Antipsicóticos/uso terapêutico , Esquizofrenia/tratamento farmacológico , Antipsicóticos/sangue , Benzodiazepinas/farmacocinética , Benzodiazepinas/uso terapêutico , Química Farmacêutica , Ensaios Clínicos como Assunto , Clozapina/farmacocinética , Clozapina/uso terapêutico , Sistema Enzimático do Citocromo P-450/metabolismo , Dibenzotiazepinas/farmacocinética , Dibenzotiazepinas/uso terapêutico , Interações Medicamentosas , Monitoramento de Medicamentos , Humanos , Estrutura Molecular , Olanzapina , Piperazinas/farmacocinética , Piperazinas/uso terapêutico , Fumarato de Quetiapina , Risperidona/farmacocinética , Risperidona/uso terapêutico , Esquizofrenia/sangue , Esquizofrenia/fisiopatologia , Tiazóis/farmacocinética , Tiazóis/uso terapêutico
18.
J Chromatogr A ; 1051(1-2): 253-60, 2004 Oct 08.
Artigo em Inglês | MEDLINE | ID: mdl-15532581

RESUMO

Mirtazapine is a recent noradrenergic and specific serotonergic antidepressant drug. A capillary electrophoretic method has been developed for the enantioseparation and analysis of mirtazapine and its main active metabolite, N-desmethylmirtazapine, in human plasma. For method optimisation several experimental parameters were investigated, such as type and concentration of the chiral selector, buffer pH and capillary temperature. Baseline enantioseparation of the analytes was achieved in 2.5 min in a fused silica capillary (50 microm i.d.; 48.5 cm total length; 8.5 cm effective length) using carboxymethyl-beta-cyclodextrin, dissolved in a background electrolyte consisting of 50 mM phosphate buffer at pH 2.5, as the chiral selector. UV detection was set at 205 nm. A careful pre-treatment of plasma samples was developed, using solid-phase extraction with hydrophilic-lipophilic balance cartridges (60 mg, 3 mL), eluting the sample with methanol, then concentrating it 37.5 times before injection. Extraction yield values are very satisfactory, being the average 89% for mirtazapine and 73% for N-desmethylmirtazapine. Application of the method to some human plasma samples has given satisfactory results.


Assuntos
Antidepressivos/sangue , Eletroforese Capilar/métodos , Mianserina/análogos & derivados , Mianserina/sangue , Humanos , Mirtazapina , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrofotometria Ultravioleta , Estereoisomerismo
19.
J Chromatogr B Analyt Technol Biomed Life Sci ; 770(1-2): 217-25, 2002 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-12013229

RESUMO

A rapid and feasible method was developed for the analysis of carbamazepine and its five metabolites (10,11-dihydro-10,11-epoxycarbamazepine, 10,11-dihydro-10,11-dihydroxycarbamazepine, 10,11-dihydro-10-hydroxycarbamazepine, 2-hydroxycarbamazepine and 3-hydroxycarbamazepine) in human plasma. Separation of the analytes is based on micellar electrokinetic chromatography, in untreated fused-silica capillary (48.5/40.0 cm length, 50 microm I.D.) with phosphate buffer (30 mM, pH 8.00) as background electrolyte, containing 50 mM sodium dodecylsulfate, and methanol (15%, v/v) as organic modifier. Clean up of human plasma samples was carried out by means of a solid-phase extraction procedure, which gave a high extraction yield for all six carbamazepines (>88%). The overall precision of the method gives a mean RSD of about 1.8%. The limit of quantitation for all analytes is < or = 0.30 microg ml(-1), the limit of detection < or = 0.12 microg ml(-1).


Assuntos
Anticonvulsivantes/sangue , Carbamazepina/sangue , Cromatografia Capilar Eletrocinética Micelar/métodos , Calibragem , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
20.
Artigo em Inglês | MEDLINE | ID: mdl-12860039

RESUMO

A simple and highly sensitive high-performance liquid chromatographic (HPLC) method for the simultaneous determination of cis(Z)-clopenthixol and trans(E)-clopenthixol in human plasma has been developed. The chromatographic analysis was carried out isocratically on a reversed-phase column (C(8) 150 x 4.6 mm I.D., 5 microm) using a mixture of 25 mM phosphate buffer and acetonitrile (65:35 v/v, pH* 3.0) as the mobile phase, and ultraviolet detection at 230 nm. Plasma sample pretreatment was accomplished by means of an original solid-phase extraction (SPE) procedure carried out on cyanopropyl cartridges, with a high extraction yield and good selectivity. Under the optimum conditions, calibration graphs of spiked human plasma samples were obtained over the concentration ranges 1-300 ng ml(-1) for cis(Z)-clopenthixol and 1-200 ng ml(-1) for trans(E)-clopenthixol. The limit of detection (LOD) was 0.3 ng ml(-1) for both cis(Z)- and trans(E)-isomers of clopenthixol. The method was successfully applied to the determination of cis(Z)-clopenthixol and trans(E)-clopenthixol in plasma samples of schizophrenic patients undergoing therapy with zuclopenthixol.


Assuntos
Antipsicóticos/sangue , Cromatografia Líquida de Alta Pressão/métodos , Clopentixol/sangue , Antipsicóticos/química , Calibragem , Clopentixol/química , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Estereoisomerismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA